A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis

Trial Profile

A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs PF 6823859 (Primary)
  • Indications Dermatomyositis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 1 Jul 2020 to 25 Mar 2020.
    • 19 Jul 2017 Planned primary completion date changed from 1 Feb 2020 to 27 Oct 2019.
    • 05 Jul 2017 Planned primary completion date changed from 26 Jan 2020 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top